(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4 days till quarter result
(amc 2024-05-02)
Expected move: +/- 2.37%
@ $270.69
Utstedt: 26 apr 2024 @ 21:51
Avkastning: -0.26%
Forrige signal: apr 26 - 19:55
Forrige signal:
Avkastning: -0.03 %
Live Chart Being Loaded With Signals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas...
Stats | |
---|---|
Dagens volum | 2.44M |
Gjennomsnittsvolum | 2.95M |
Markedsverdi | 144.69B |
EPS | $0 ( 2024-04-25 ) |
Neste inntjeningsdato | ( $3.76 ) 2024-05-02 |
Last Dividend | $2.25 ( 2024-02-15 ) |
Next Dividend | $0 ( N/A ) |
P/E | 21.60 |
ATR14 | $5.96 (2.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Santos Esteban | Sell | 6 137 | Common Stock |
2024-03-18 | Reese David M | Sell | 6 202 | Common Stock |
2024-03-18 | Miller Derek | Sell | 475 | Common Stock |
2024-03-18 | Khosla Rachna | Sell | 438 | Common Stock |
2024-03-18 | Grygiel Nancy A. | Sell | 703 | Common Stock |
INSIDER POWER |
---|
58.82 |
Last 97 transactions |
Buy: 472 102 | Sell: 97 922 |
Volum Korrelasjon
Amgen Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
SMIT | 0.929 |
CNCE | 0.926 |
PLIN | 0.925 |
CTIC | 0.921 |
RETA | 0.921 |
LAWS | 0.921 |
PIII | 0.917 |
IMTX | 0.914 |
OP | 0.913 |
OBT | 0.912 |
10 Mest negative korrelasjoner | |
---|---|
RGLD | -0.945 |
GRFS | -0.941 |
IMVT | -0.939 |
WB | -0.936 |
HCM | -0.934 |
HERA | -0.934 |
SOCL | -0.933 |
HOFT | -0.933 |
IPKW | -0.93 |
HERAU | -0.929 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Amgen Inc Korrelasjon - Valuta/Råvare
Amgen Inc Økonomi
Annual | 2023 |
Omsetning: | $28.19B |
Bruttogevinst: | $19.74B (70.02 %) |
EPS: | $12.56 |
FY | 2023 |
Omsetning: | $28.19B |
Bruttogevinst: | $19.74B (70.02 %) |
EPS: | $12.56 |
FY | 2022 |
Omsetning: | $26.32B |
Bruttogevinst: | $19.92B (75.66 %) |
EPS: | $12.18 |
FY | 2021 |
Omsetning: | $25.98B |
Bruttogevinst: | $19.53B (75.16 %) |
EPS: | $10.06 |
Financial Reports:
No articles found.
Amgen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$1.940 (N/A) |
$1.940 (N/A) |
$2.13 (N/A) |
$2.13 (N/A) |
$2.13 (N/A) |
$2.13 (N/A) |
$2.25 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.280 | 2011-08-16 |
Last Dividend | $2.25 | 2024-02-15 |
Next Dividend | $0 | N/A |
Payout Date | 2024-03-07 | |
Next Payout Date | N/A | |
# dividends | 51 | -- |
Total Paid Out | $61.13 | -- |
Avg. Dividend % Per Year | 2.40% | -- |
Score | 5.46 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.55 | |
Div. Directional Score | 8.29 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0.560 | 1.01% |
2012 | $1.440 | 2.25% |
2013 | $1.880 | 2.11% |
2014 | $2.44 | 2.11% |
2015 | $3.16 | 1.98% |
2016 | $4.00 | 2.53% |
2017 | $4.60 | 3.05% |
2018 | $5.28 | 2.98% |
2019 | $5.80 | 3.02% |
2020 | $6.40 | 2.67% |
2021 | $7.04 | 3.11% |
2022 | $7.76 | 3.42% |
2023 | $8.52 | 3.26% |
2024 | $2.25 | 0.76% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.238 | 1.500 | 5.23 | 7.85 | [0 - 0.5] |
returnOnAssetsTTM | 0.0691 | 1.200 | 7.70 | 9.23 | [0 - 0.3] |
returnOnEquityTTM | 1.033 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.678 | -1.000 | 3.22 | -3.22 | [0 - 1] |
currentRatioTTM | 1.649 | 0.800 | 6.75 | 5.40 | [1 - 3] |
quickRatioTTM | 1.622 | 0.800 | 5.17 | 4.13 | [0.8 - 2.5] |
cashRatioTTM | 0.595 | 1.500 | 7.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.665 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 3.15 | 1.000 | 9.94 | 9.94 | [3 - 30] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 3.12 | 6.24 | [0 - 20] |
debtEquityRatioTTM | 10.37 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.700 | 1.000 | 1.663 | 1.663 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.321 | 1.000 | 5.57 | 5.57 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.131 | 1.000 | -0.383 | -0.383 | [0.2 - 2] |
assetTurnoverTTM | 0.290 | 0.800 | -1.399 | -1.119 | [0.5 - 2] |
Total Score | 10.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.50 | 1.000 | 7.93 | 0 | [1 - 100] |
returnOnEquityTTM | 1.033 | 2.50 | 3.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 13.76 | 2.00 | 5.41 | 6.24 | [0 - 30] |
dividendYielPercentageTTM | 3.20 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 15.83 | 2.00 | 4.72 | 9.44 | [0 - 30] |
payoutRatioTTM | 0.678 | 1.500 | 3.22 | -3.22 | [0 - 1] |
pegRatioTTM | 0.622 | 1.500 | 9.19 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.300 | 1.000 | 4.99 | 0 | [0.1 - 0.5] |
Total Score | 6.55 |
Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.